# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to b...
Phase 2b Data Presented at EASL and Published in NEJM Show Potential for Bulevirtide 10 mg in Combination with Pegylated Inte...
- Positive Results from Two-year Interim Analysis Includes Participants from Phase 3 RESPONSE Study and are Highly Consistent...
The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender w...
https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-agreement-in-principle-to-resolve-federal-tdf-liti...
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cance...